Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
Jianfeng Zheng,
Wenjuan Chen,
Xuemei Yi
et al.
Abstract:BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.MethodsA retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.